Serum adiponectin levels in adult growth hormone deficiency and acromegaly. 2004

Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. izumif@endm.twmu.ac.jp

Atherosclerosis and insulin resistance are common complications of adult growth hormone deficiency (GHD) and acromegaly. Circulating adiponectin, an adipocyte-derived protein, has both anti-atherogenic and insulin-sensitising effects. In this study, we measured serum adiponectin levels in patients with either adult GHD or acromegaly to clarify the impact of GH secretory states on the regulation of serum adiponectin levels. Serum adiponectin level was measured by radioimmunoassay in 32 patients with adult GHD, 49 patients with acromegaly and 25 normal subjects. The relationships between adiponectin and insulin sensitivity index assessed as quantitative insulin sensitivity check index (QUICKI), BMI, and serum GH and IGF-I levels were then investigated. The values of QUICKI were significantly lower in patients with acromegaly or adult GHD compared to normal subjects (0.33 +/- 0.03, P < 0.01, 0.35 +/- 0.04, P < 0.05 and 0.36 +/- 0.01, respectively). While patients with adult GHD had significantly lower serum adiponectin levels than patients with acromegaly (6.5 +/- 3.9, 9.2 +/- 5.0, P < 0.01) these levels were not significantly different from those found in normal subjects (7.8 +/- 4.3 mug/ml). There was an inverse correlation between serum adiponectin levels and BMI in both patient groups (GHD r = -0.39, P < 0.05; Acromegaly r = -0.35, P < 0.05). However, serum adiponectin levels correlated positively with QUICKI (R(s) = 0.37, P < 0.05) only in patients with adult GHD. In patients with acromegaly, the levels of circulating adiponectin showed an inverse correlation with serum IGF-I levels (R(s) = -0.34, P < 0.05), but not with basal GH levels. These results demonstrate that adiponectin levels are significantly lower in patients with adult GHD than in patients with acromegaly. Adiponectin levels are similar in patients with GHD and healthy controls, whereas in patients with acromegaly, insulin resistance appears to be not closely related to adiponectin levels compared with BMI. The different relationship between adiponectin and QUICKI observed in the adult GHD and acromegaly groups presumably reflects differences in the mechanisms of insulin resistance under states of GH deficiency or excess.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
May 2017, Neuro endocrinology letters,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
July 2006, Archives of medical research,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
October 2005, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
April 1977, British medical journal,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
September 1988, Postgraduate medical journal,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
November 2004, The Journal of clinical endocrinology and metabolism,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
January 2015, Trends in endocrinology and metabolism: TEM,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
February 2014, Genetics and molecular research : GMR,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
September 1992, Journal of internal medicine,
Izumi Fukuda, and Naomi Hizuka, and Yukiko Ishikawa, and Emina Itoh, and Kumiko Yasumoto, and Yuko Murakami, and Akira Sata, and Junko Tsukada, and Makiko Kurimoto, and Yumiko Okubo, and Kazue Takano
January 2006, Physiological research,
Copied contents to your clipboard!